Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment

There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite this progress, treatment options remain limited, underscoring the need to continue to expand the treatment armamentarium. Even with pharmacotherapeutic advances, however, the need to accurately diagnose patients remains vital. Increased disease awareness, early recognition of signs/symptoms, and appropriate diagnostic testing are essential to the timely initiation of treatment and the ultimate goal of optimizing patient quality of life and long-term prognosis. The CME Circuit Training™ platform provides an engaging, self-directed educational experience that not only addresses these topics but prepares clinicians to effect positive changes in ATTR amyloidosis care.